Jason Fontenot, Ph.D., Joins Immusoft as Chief Scientific Officer

Immusoft Corporation, a Seattle, Wash.-based biopharmaceutical company
focused on reengineering the body’s B cells to treat diseases, announced
today that Jason D. Fontenot, Ph.D., has joined its leadership team as
Chief Scientific Officer.

Dr. Fontenot has extensive research and drug development expertise, most
recently serving as the Head of Exploratory Research at Juno
Therapeutics, which was acquired by Celgene for $9 billion earlier this
year.

He is an internationally recognized immunologist with expertise in
immune cell biology, cell engineering and immune-mediated disease. The
groundbreaking work that Dr. Fontenot and his colleagues conducted on
regulatory T cells and the transcription factor, FOXP3, transformed the
study of immune regulation and has resulted in some of the most highly
cited publications in the field of immunology in the last 20 years.

“I am very excited to join Immusoft,” says Dr. Fontenot. “They have
developed a remarkable and robust cell therapy platform that has the
potential to revolutionize the treatment of human diseases in multiple
therapeutic areas. I look forward to building and expanding upon
Immusoft’s foundational work to develop potentially curative therapies
for patients.”

While at Juno Therapeutics, Dr. Fontenot was responsible for advancing
the company’s early stage engineered T cell therapy pipeline and
overseeing the development of next generation cellular and genetic
engineering strategies in collaboration with internal and external
partners. He also managed major research partnerships with leading
biotech and academic institutions.

“Jason is a substantial addition to the Immusoft team, and we are
pleased that he has chosen to join us,” says Sean Ainsworth, Immusoft’s
CEO and Chairman of the Board. “He has the breadth and depth of
experience to deepen our understanding of the immune system and modified
B cell therapy. We expect his contributions to help us rapidly advance
our current programs and extend our platform.”

Prior to his time at Juno Therapeutics, Dr. Fontenot worked for nearly a
decade as a group leader in the immunology department at Biogen in
Cambridge, Mass., where his team focused on T cell biology and immune
regulation. He worked on several high profile immunomodulatory drug
development programs.

ABOUT IMMUSOFTImmusoft Corporation’s (immusoft.com)
mission is to treat diseases using its breakthrough technology platform
called Immune System Programming (ISP™). The technology modifies a
patient’s B cells and instructs the cells to produce gene-encoded
medicines (biologics). The B cells that are reprogrammed using ISP
become miniature drug factories that are expected to survive in patients
for many years. Founded in 2009, Immusoft is based in Seattle, Wash.

FORWARD-LOOKING STATEMENTSStatements in this press release
that are not strictly historical are forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on management’s current plans,
estimates and projections. The beliefs, assumptions and expectations on
which these statements are based can change as a result of many possible
events or factors, not all of which are known to Immusoft Corporation or
are within its control. Immusoft Corporation undertakes no obligation to
update any forward-looking statement in light of new information or
future events. Actual results or outcomes may differ from those implied
by the forward-looking statements as a result of a number of
operational, scientific, regulatory and related risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005320/en/

Leave a Comment